Pembrolizumab Injection [Keytruda]
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urologic Cancer
Conditions
Urologic Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate
Trial Timeline
Oct 20, 2022 → Apr 1, 2026
NCT ID
NCT04931979About Pembrolizumab Injection [Keytruda]
Pembrolizumab Injection [Keytruda] is a phase 2 stage product being developed by Merck for Urologic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04931979. Target conditions include Urologic Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06180733 | Phase 2 | Recruiting |
| NCT04931979 | Phase 2 | Recruiting |
| NCT04303884 | Phase 2 | UNKNOWN |
Competing Products
16 competing products in Urologic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| Mirabegron + Solifenacin succinate + Placebo | Astellas Pharma | Phase 2 | 52 |
| Mirabegron + Solifenacin succinate | Astellas Pharma | Phase 3 | 77 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| ALIMTA + gemcitabine | Eli Lilly | Phase 2 | 52 |
| BBI503 | Sumitomo Pharma | Phase 2 | 52 |
| Carboplatin/Paclitaxel + Pembrolizumab | Merck | Phase 2 | 52 |
| zoledronic acid | Novartis | Phase 2 | 52 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| CBT101 + Placebo | Brain Biotech | Phase 1 | 25 |
| OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin | Achieve Life Sciences | Phase 2 | 44 |
| S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel | Achieve Life Sciences | Phase 2 | 44 |
| Stem Cell | Brain Biotech | Phase 1 | 25 |